Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells.

Huang L, Hu C, DI Benedetto M, Varin R, Liu J, Jin J, Wang L, Vannier JP, Janin A, Lu H, Li H.

Oncol Lett. 2015 Mar;9(3):1287-1292. Epub 2014 Dec 22.

2.

Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib.

Huang L, Hu C, Di Benedetto M, Varin R, Liu J, Wang L, Vannier JP, Jin J, Janin A, Lu H, Li H.

Onco Targets Ther. 2014 Dec 4;7:2249-55. doi: 10.2147/OTT.S67251. eCollection 2014.

3.

Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy.

Huang L, Perrault C, Coelho-Martins J, Hu C, Dulong C, Varna M, Liu J, Jin J, Soria C, Cazin L, Janin A, Li H, Varin R, Lu H.

J Hematol Oncol. 2013 Jul 9;6:49. doi: 10.1186/1756-8722-6-49.

4.

Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.

Fiorio Pla A, Brossa A, Bernardini M, Genova T, Grolez G, Villers A, Leroy X, Prevarskaya N, Gkika D, Bussolati B.

BMC Cancer. 2014 Dec 12;14:939. doi: 10.1186/1471-2407-14-939.

5.

Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.

Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS.

Biochim Biophys Acta. 2014 Jan;1840(1):615-25. doi: 10.1016/j.bbagen.2013.10.023. Epub 2013 Oct 24.

PMID:
24161697
6.
7.

Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.

Xia YZ, Ni K, Guo C, Zhang C, Geng YD, Wang ZD, Yang L, Kong LY.

Phytomedicine. 2015 Mar 15;22(3):344-51. doi: 10.1016/j.phymed.2014.12.011. Epub 2015 Jan 28.

PMID:
25837271
8.

Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.

Zaja R, Caminada D, Loncar J, Fent K, Smital T.

Toxicol Appl Pharmacol. 2008 Mar 1;227(2):207-18. Epub 2007 Nov 13.

PMID:
18076962
9.

Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.

Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP.

Mol Cancer Ther. 2008 Jul;7(7):2152-9. doi: 10.1158/1535-7163.MCT-08-0021.

10.

Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.

Xu HB, Shen ZL, Fu J, Xu LZ.

Phytomedicine. 2014 Sep 25;21(11):1221-9. doi: 10.1016/j.phymed.2014.06.003. Epub 2014 Jul 25.

PMID:
25172783
11.

Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.

Wu Y, Zhang Y, Zhang W, Sun C, Wu J, Tang J.

Colloids Surf B Biointerfaces. 2016 Feb 1;138:60-9. doi: 10.1016/j.colsurfb.2015.11.041. Epub 2015 Nov 25.

PMID:
26655793
12.

Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.

Wang X, Teng Z, Wang H, Wang C, Liu Y, Tang Y, Wu J, Sun J, Wang H, Wang J, Lu G.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1337-47. eCollection 2014.

13.

Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.

Datta A, Bhasin N, Kim H, Ranjan M, Rider B, Abd Elmageed ZY, Mondal D, Agrawal KC, Abdel-Mageed AB.

Cancer Lett. 2015 Jun 28;362(1):25-35. doi: 10.1016/j.canlet.2015.03.009. Epub 2015 Mar 18.

PMID:
25796439
14.

Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells.

Cui XY, Skretting G, Jing Y, Sun H, Sandset PM, Sun L.

Blood Cells Mol Dis. 2013 Oct;51(3):177-84. doi: 10.1016/j.bcmd.2013.05.003. Epub 2013 May 29.

PMID:
23725749
15.

Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway.

Shinoda C, Maruyama M, Fujishita T, Dohkan J, Oda H, Shinoda K, Yamada T, Miyabayashi K, Hayashi R, Kawagishi Y, Fujita T, Matsui S, Sugiyama E, Muraguchi A, Kobayashi M.

Int J Cancer. 2005 Oct 20;117(1):21-31.

16.

Protein kinase Cα protects against multidrug resistance in human colon cancer cells.

Lee SK, Shehzad A, Jung JC, Sonn JK, Lee JT, Park JW, Lee YS.

Mol Cells. 2012 Jul;34(1):61-9. doi: 10.1007/s10059-012-0087-1. Epub 2012 May 23.

17.

Troglitazone reverses the multiple drug resistance phenotype in cancer cells.

Davies GF, Juurlink BH, Harkness TA.

Drug Des Devel Ther. 2009 Sep 21;3:79-88.

18.

Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.

Amornsupak K, Insawang T, Thuwajit P, O-Charoenrat P, Eccles SA, Thuwajit C.

BMC Cancer. 2014 Dec 15;14:955. doi: 10.1186/1471-2407-14-955.

19.

Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.

Lv L, Qiu K, Yu X, Chen C, Qin F, Shi Y, Ou J, Zhang T, Zhu H, Wu J, Liu C, Li G.

J Biomed Nanotechnol. 2016 May;12(5):973-85.

PMID:
27305819
20.

Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.

Han KS, Raven PA, Frees S, Gust K, Fazli L, Ettinger S, Hong SJ, Kollmannsberger C, Gleave ME, So AI.

Neoplasia. 2015 Nov;17(11):805-16. doi: 10.1016/j.neo.2015.11.001.

Supplemental Content

Support Center